-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The FDA announced today that it will limit the emergency use authorization (EUA) of Johnson & Johnson's COVID-19 vaccine Ad2COVS to people 18 and older who do not have access to other coronavirus vaccin.
FDA COVID-19 Thrombosis
Thrombosis and thrombocytopenia syndrome (TTS) is characterized by coagulation (thrombosis) and thrombocytopen.
"We recognize that vaccines still have a role to play in the current pandemic response in the.
People may develop TTS symptoms about one to two weeks after receiving Johnson & Johnson's vaccine, the FDA sa.
Currently, Ad2COVS is far less used than two other coronavirus vaccines currently approved in the US: Pfizer/BioNTech's Comirnaty and Moderna's Spikevax, both of which are mRNA vaccin.
prevention
Meanwhile, following a December 2021 meeting, the CDC's Vaccine Advisory Committee voted unanimously to recommend that mRNA vaccines (Comirnaty or Spikevax) be given priority over Ad2COVS when availab.
Meanwhile, following a December 2021 meeting, the CDC's Vaccine Advisory Committee voted unanimously to recommend that mRNA vaccines (Comirnaty or Spikevax) be given priority over Ad2COVS when availab.
Original source:
Original source:https://firstwordphar.
https://firstwordphar.
com/story/5564945 https://firstwordphar.
com/story/5564945Leave a comment here
